Dr. Waksal is the author of 50 published scientific papers, many in the area of oncology. He currently serves on a number of non-corporate boards, including the American Committee for the Weizmann Institute of Science in New York, NY, Oberlin College in Oberlin, OH and the Montclair Art Museum in Montclair, NJ. Dr. Waksal also serves on the Technology Advisory Board for the New Jersey Edison Innovation Fund.
He earned his B.A. in biology from Oberlin College in 1975, and received his M.D. from Tufts University School of Medicine, Boston, MA.
About Senesco Technologies, Inc.
Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.
Certain statements included in this press release are forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995. Actual results could differ materially from such statements
|SOURCE Senesco Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved